“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukaemia (CLL) cells and the common side-effects experienced by these drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.”